Stay informed with the latest updates for the inheritable blood disorders community. Industry Baxter Announces Phase 3 Study Data for rVWF TherapyMay 1, 2014 Industry Biogen Announces Longer-Acting FVIII Study Results in KidsMay 1, 2014 IndustryNovo Nordisk Reports Results of Long-Acting rVIII ProductApr 1, 2014 IndustryBayer Reports Progress for Longer-Acting rFVIII ProductMar 1, 2014 IndustryFDA Grants Breakthrough Designation for Bristol-Myers Squibb Oral HCV…Mar 1, 2014 IndustryGilead Files NDA for HCV Combination TherapyMar 1, 2014 IndustryGrifols Changes Name of Hemophilia A StudyFeb 1, 2014 IndustryPhase 1 Trial Begins for Alnylam's ALN-AT3Feb 1, 2014 IndustryBiogen and Swedish Orphan Biovitrum Announce Results of Longer-…Jan 1, 2014 IndustryBaxter Seeks Pediatric Indication from FDA for RIXUBISJan 1, 2014 IndustryEnrollment Complete for Baxter's PROLONG-ATE StudyDec 1, 2013 IndustryProgress and Delay for Biogen's Longer-Lasting rFVIII TherapyDec 1, 2013 IndustryFDA Approves BLA for Novo Nordisk's New rFVIII ProductNov 1, 2013 IndustryBoehringer Fills Trial for Interferon-free HCV TherapyOct 1, 2013 IndustrySernova and Medicyte Collaborate on Hemophilia A TherapyOct 1, 2013 Pagination First page Previous page … Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Page 21 … Next page Last page
